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Abstract: The occurrence of skeletal muscle atrophy, a devastating complication of a large number of disease 
states and inactivity/disuse conditions, provides a never ending quest to identify novel targets for its therapy. 
Proinflammatory cytokines are considered the mediators of muscle wasting in chronic diseases; however, their 
role in disuse atrophy has just begun to be elucidated. An inflammatory cytokine, tumor necrosis factor (TNF)-
like weak inducer of apoptosis (TWEAK), has recently been identified as a potent inducer of skeletal muscle 
wasting. TWEAK activates various proteolytic pathways and stimulates the degradation of myofibril protein 
both  in vitro and in vivo. Moreover, TWEAK mediates the loss of skeletal muscle mass and function in 
response to denervation, a model of disuse atrophy. Adult skeletal muscle express very low to minimal levels 
of TWEAK receptor, Fn14. Specific catabolic conditions such as denervation, immobilization, or unloading 
rapidly increase the expression of Fn14 in skeletal muscle which in turn stimulates the TWEAK activation of 
various catabolic pathways leading to muscle atrophy. In this article, we have discussed the emerging roles 
and the mechanisms of action of TWEAK-Fn14 system in skeletal muscle with particular reference to different 
models of muscle atrophy and injury and its potential to be used as a therapeutic target for prevention of 
muscle loss. 
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INTRODUCTION 
Skeletal muscle wasting/atrophy is the major human 
morbidity observed during aging, a wide variety of 
chronic disease states (e.g. diabetes, chronic 
obstructive pulmonary
  disease, heart
  failure, renal 
failure, and cancer), disuse conditions (e.g. 
immobilization, denervation and unloading), and high 
dosage glucocorticoid therapy [1, 2]. Skeletal muscle 
wasting results from either enhanced protein 
degradation or reduced synthesis or both [1, 3, 4]. 
Diverse physiological and pathophysiological stimuli 
trigger muscle atrophy through the activation of specific 
intracellular signaling pathways and proteolytic 
systems. Generally, the insulin growth factor-1 (IGF-
1)/insulin/ phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway is considered as an anabolic pathway leading 
to increased protein synthesis and skeletal muscle 
hypertrophy [5-7]. On the other hand, activation of 
specific signaling proteins such as c-Jun-N-terminal 
kinase (JNK), p38 mitogen-activated protein kinase 
(MAPK), and AMP-activated protein kinase (AMPK) 
and/or transcription factors such as nuclear factor-B 
(NF-B), activator protein-1, p53, and Foxo lead to the 
loss of skeletal muscle mass through augmenting the 
activity of ubiquitin-proteasome system (UPS), 
autophagy, and caspases [8-19].  
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Whereas remarkable progress has been made 
towards understanding the intracellular pathways, little 
is known about the triggers and/or initial events 
responsible for loss of skeletal muscle mass in various 
catabolic states. Inflammatory cytokines have been 
suggested to induce and mediate local catabolic 
mechanisms at advanced stages of chronic diseases 
leading to the syndrome of cachexia [12, 20, 21]. 
However, their role in muscle atrophy in disuse 
conditions has just begun to be unfolded. Recent 
investigations have led to the identification of TWEAK-
Fn14 system as a major regulator of skeletal muscle 
mass in both physiological and pathophysiological 
conditions. TWEAK appears to be the first cytokine 
involved in muscle wasting in disuse conditions. In this 
article, we have reviewed the current knowledge and 
discussed the mechanisms by which TWEAK-Fn14 
system regulates skeletal muscle remodeling in 
different conditions.  
OVERVIEW OF TWEAK-FN14 SYSTEM 
TWEAK is a type II transmembrane protein and 
member 12 of the TNF super family (TNFSF) [22]. 
TWEAK is initially synthesized as a type II 
transmembrane protein, cleaved to its soluble form, 
and signals as a trimerized molecule [22, 23]. Both 
membrane-bound and soluble TWEAK proteins are 
fully functional though what regulates their relative 
abundance in specific conditions remains unknown. 
Fibroblast growth factor-inducible 14 (Fn14), a type I 
transmembrane protein was first recognized by 
differential display technique and later identified as the 
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of TNF receptor super family (TNFRSF). Its 
cytoplasmic domain contains a TNF receptor-
associated factor (TRAF) binding site that allows 
recruitment of various TRAFs, which are also involved 
in cell signaling by other members of TNFSF [27]. One 
unique aspect of Fn14 not shared by other members of 
TNFRSF is that the expression of Fn14 is highly 
modulated under the influence of a wide variety of 
stimuli and conditions [23]. TWEAK-Fn14 dyad 
regulates several physiological responses including cell 
survival, proliferation, angiogenesis, migration, and 
apoptosis [23]. In contrast, increased expression of 
TWEAK and/or Fn14 is linked to pathogenesis in 
rheumatoid arthritis, systemic lupus erythematosus, 
multiple sclerosis, renal injury, stroke, neuroinflam-
mation and neurodegeneration, several types of 
cancer, and cardiac dysfunction and failure [23, 28].  
Like many other TNFSF members, TWEAK-Fn14 
signaling mediates unique and context-dependent 
pleiotropic effects. For example, in contrast to TNF-, 
TWEAK attenuates the transition from
  innate to 
adaptive immunity by suppressing
  the production of 
interferon- and IL-12 cytokines [29]. TWEAK has been 
shown to activate p44/p42 MAPK, c-Jun N-terminal 
kinase (JNK), transcription factor activator protein-1 
(AP-1), and NF-B signaling pathway in various cell 
types including skeletal muscle [30-33]. It has been 
suggested that binding of TWEAK to Fn14 extracellular 
domain leads to receptor trimerization, association of 
TRAF2/cIAP1 (cellular inhibitor of apoptosis protein 1) 
complex to cytoplasmic domain, and subsequent 
activation of various signaling proteins including 
TRAF6, transforming growth factor- activated kinase1 
(TAK1), I kappa B kinase (IKK), and MAPKs leading to 
altered expression of several genes involved in various 
cellular responses (Fig. 1) [23, 30, 34-36]. TWEAK and 
Fn14 appear to have a minimal role in embryonic 
development or postnatal growth because mice null for 
TWEAK or Fn14 are viable and show no major 
abnormalities [29, 37, 38]. 
TWEAK-Fn14 SYSTEM AND MUSCLE ATRO-
PHY 
Although classical inflammatory cytokines are 
known to cause muscle wasting, the limited success of 
anti-TNF- or anti-IL-1 therapy in prevention of 
muscle loss has suggested that there might be other 
mediators of skeletal muscle wasting [39, 40]. Using 
C2C12 myotubes as a model system, we previously 
evaluated the effects of several members of TNFSF on 
myotube size. These initial experiments revealed that 
treatment with physiological concentrations of TWEAK 
causes significant reduction in myotube diameter [41]. 
Muscle wasting involves the degradation of selective 
muscle proteins and myosin heavy chain (MyHC) is 
one such protein that undergoes rapid proteolysis in 
different atrophic conditions such as denervation, 
starvation, tumor load, and in response to inflammatory 
cytokines [34, 42, 43]. Consistent with its catabolic role 
in myotubes, TWEAK was found to reduce the levels of 
MyHC in cultured myotubes in a dose-dependent 
manner [41].  
The UPS is a major proteolytic system that causes 
selective degradation of regulatory and structural 
proteins in skeletal muscle [44, 45]. Almost a decade 
back, two muscle-specific E3 ubiquitin ligases, muscle 
RING-finger 1 (MuRF1) and muscle
  atrophy F-box 
(MAFbx; also known as Atrogin-1) were identified [46, 
47]. The expression of MuRF1 and MAFbx has been 
found to be increased in multiple models of skeletal 
muscle atrophy [46-48]. Catabolic role of these 
ubiquitin ligases has been validated by the findings that 
muscle wasting is considerably inhibited in mice null for 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The TWEAK-Fn14 signaling system. Binding of 
TWEAK to Fn14 receptors leads to the recruitment of cIAP1, 
TRAF-2, 5, and/or 6 proteins leading to downstream 
activation of transforming growth factor -activated kinase 1 
(TAK1), NF-B inducing kinase (NIK), and various mitogen-
activated protein kinase kinases (MKK). Activation of TAK1 
stimulates IB kinase  (IKK) leading to the activation of 
canonical NF-B. NIK phosphorylates and activates IKK 
leading to downstream activation of NF-B through 
alternative pathway. Various MKKs activate c-Jun N-terminal 
kinase 1 (JNK1) and p38 MAPK, which in turn activate 
transcription factor activator protein-1 (AP-1). Increased 
activation of NF-B and AP-1 leads to the expression of 
specific genes resulting in TWEAK-mediated responses.  
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MuRF1 or MAFbx compared to wild-type in response
 to 
a wide variety of stimuli [46-48]. Accumulating evidence 
also suggests that MuRF1 targets specific thick 
filament proteins including MyHC for proteolysis in 
skeletal muscle [49, 50]. 
Cell culture studies showed that the treatment with 
TWEAK increases the expression of muscle-specific 
E3 ubiquitin ligases MuRF1 and MAFbx and stimulates 
the conjugation of ubiquitin with MyHC in C2C12 
myotubes suggesting that TWEAK causes degradation 
of MyHC through the activation of UPS [41]. More 
recently, we have reported that TWEAK can also 
induce the expression of components of the 
autophagy-lysosomal system and activates caspases 
especially caspase-3 in cultured myotubes, which may 
also contribute to myofibrillar proteolysis [51]. 
Furthermore, TWEAK inhibits the activity of PI3K/Akt 
signaling pathway which further explains the strong 
catabolic actions of TWEAK in cultured myotubes [41].  
The  in vivo effects of TWEAK on skeletal muscle 
were investigated by chronic administration of soluble 
TWEAK protein in wild-type mice and through 
generation of muscle-specific TWEAK-transgenic (Tg) 
mice. Treatment of mice with TWEAK led to a 
significant reduction in body weight and individual hind 
limb muscle weight and fiber-cross-sectional area 
compared to untreated littermates [41]. Furthermore, 
transgenic overexpression of full-length TWEAK cDNA 
using muscle creatine kinase promoter showed 
profound loss of skeletal muscle mass and neonatal 
lethality (in high copy number transgenic founder) in 
mice [41]. Founder TWEAK-Tg mice were smaller in 
size and had difficulty in breathing and motion. 
TWEAK-Tg mice which survived due to relatively low 
expression of TWEAK (4-6 folds higher than littermate 
wild-type mice) showed atrophy and interstitial fibrosis 
around six months of age [34]. Consistent with in vitro 
studies, the activation of NF-B, levels of MuRF1, and 
ubiquitination of MyHC were significantly elevated in 
skeletal muscle of TWEAK-treated or TWEAK-Tg mice 
compared to their corresponding controls indicating 
that TWEAK causes muscle wasting through activation 
of NF-B and enhancing the expression of the 
components of UPS especially MuRF1 [41]. 
Interestingly, while TWEAK induced the expression of 
MAFbx in cultured myotubes [41], there was no 
significant difference in mRNA levels of MAFbx in 
skeletal muscle of wild-type and TWEAK-Tg mice 
indicating that TWEAK might be causing muscle-
wasting  in vivo specifically by augmenting the 
expression of MuRF1 [41].  
The role of TWEAK-Fn14 system in physiological 
atrophy was investigated through a series of 
experiments in our laboratory. Gene array experiments 
showed that the expression of TWEAK receptor Fn14 
is regulated in the conditions of atrophy and 
hypertrophy [34]. Fn14 levels were found to be 
increased in skeletal muscle in various disuse 
conditions such as denervation and immobilization [34]. 
Recently, Wu et al. [52] studied the global gene 
expression in skeletal muscle of mice in response to 
hind-limb suspension, a model of unloading-induced 
skeletal muscle atrophy. This study identified a number 
of genes upregulated after 6 days of hind limb 
suspension [52]. Interestingly, both microarray and 
quantitative real-time PCR assays, showed that the 
expression of Fn14 is significantly increased in 
gastrocnemius muscle of mice at 6 days of hind limb 
suspension further supporting the inference that the 
expression of Fn14 goes up in various disuse 
conditions [52]. Conversely, hypertrophy stimuli such 
as recovery after cast immobilization or exercise 
reduced even the basal level of Fn14 in skeletal muscle 
[34]. It is noteworthy that TWEAK-Fn14 system is not 
involved in all types of muscular atrophy. High dose of 
glucocorticoids, which causes severe muscle-wasting, 
did not affect the levels of TWEAK or Fn14 in skeletal 
muscle of mice [34]. Similarly, the expression of either 
TWEAK or Fn14 did not change in response to 
inflammatory cytokines and endotoxin in cultured 
myotubes (our unpublished observations) further 
suggesting that TWEAK-Fn14 might be causing 
skeletal muscle wasting in only specific conditions.  
To evaluate the role of TWEAK in disuse atrophy, 
hind limb muscle of wild-type, TWEAK-Tg, and 
TWEAK-KO mice were denervated (meaning 
transection of sciatic nerve) for 10-12 days. 
Interestingly, skeletal muscle mass and functions were 
considerably preserved in TWEAK-KO mice compared 
to age-matched wild-type mice upon denervation [34]. 
In contrast, the denervation-induced muscle atrophy 
and fibrosis were significantly increased in TWEAK-Tg 
mice compared to wild-type littermates [34]. 
Furthermore, pharmacological inhibition of TWEAK 
using an TWEAK neutralizing antibody also rescued 
the denervation-induced muscle atrophy in wild-type 
mice [34]. TWEAK was found to stimulate the activation 
of NF-B and the expression of MuRF1 (but not 
MAFbx) in denervated skeletal muscle [34, 41]. 
Coincidently, this was the first report providing 
experimental evidence about the involvement of an 
inflammatory cytokine in skeletal muscle in 
disuse/denervation conditions [34]. All previous 
attempts to investigating the role of inflammatory 
cytokine in disuse atrophy were focused on classical 
muscle-wasting cytokines such as TNF-, IL-1, IL-6, 
and IFN-. Gene expression studies found no evidence 
for their involvement in disuse-related muscle atrophy 
[1, 53, 54]. 
It was interesting to note that TWEAK did not affect 
all pathways known to be involved in regulation of 
skeletal muscle mass. While TWEAK inhibits Akt 
phosphorylation in cultured myotubes [41], the level of 
phosphorylation of Akt and its downstream targets was 
comparable in denervated muscle of wild-type, 
TWEAK-Tg and TWEAK-KO mice suggesting that the 
inhibitory effect of TWEAK on PI3K/Akt pathway is 
neutralized by some other factors that may be present 
in denervated muscle in vivo [34]. Furthermore, a 
significant increase in the expressions of several 
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Atg12, and Gabarapl1) was also noticeable in skeletal 
muscle upon denervation. However, there was no 
significant difference in mRNA levels of various 
autophagy-related genes between denervated muscle 
of wild-type, TWEAK-Tg, and TWEAK-KO mice [34]. 
These studies thus indicate that TWEAK-Fn14 dyad 
specifically up-regulates the expression of the 
components of the UPS in denervated muscle. Similar 
mechanisms might be involved in other disuse 
conditions such as immobilization and unloading (Fig. 
2).  
While it is now clear that the expression of Fn14 is a 
rate-limiting step in TWEAK-mediated muscle wasting, 
the underpinning mechanisms by which Fn14 is up-
regulated in skeletal muscle in conditions of atrophy 
have not been yet investigated. Previous in silico 
analyses of the promoter regions of both human and 
mouse Fn14 gene had suggested the presence of 
consensus binding sites for a number of transcription 
factors including NF-B, AP-1, SP-1, and MyoD [55]. 
Recently, Wu et al. reported that unloading-induced 
upregulation of Fn14 is significantly inhibited in Nfkb1-
knockout mice supporting role of NF-B in the 
increased expression of Fn14 in disuse conditions [52]. 
Furthermore, Fn14 gene appears to contain CpG rich 
regions in its promoter (our unpublished observations) 
indicating that the expression of Fn14 may also be 
regulated through epigenetic mechanisms.  
In addition to activating proteolysis, TWEAK also 
up-regulates the expression of matrix 
metalloproteinases (MMPs), especially MMP-9, which 
may be responsible for extracellular matrix breakdown 
and fibrosis in atrophying skeletal muscle [30]. TWEAK 
also modulates the expression of a number of genes 
and microRNAs (miRs) known to be involved in 
manifestation of oxidative stress, mitochondrial 
abnormalities, fibrosis, and energy deficit in skeletal 
muscle [56, 57]. The precise role of specific genes and 
miRs affected by TWEAK in skeletal muscle is an 
important area for future investigations.  
TWEAK VERSUS OTHER CATABOLIC CYTO-
KINES 
Although comparative studies are still lacking, there 
appears to be some overlap as well as distinction 
between the mechanisms of action of TWEAK and 
other inflammatory cytokines such as TNF-, IL-1, 
and IL-6 in skeletal muscle wasting. This contention is 
also supported by our recent microarray studies which 
showed that TNF- and TWEAK affect the expression 
of a large number of common and distinct sets of 
genes and molecular pathways [56, 58]. A recent study 
employing cultured myotubes has suggested that TNF-
 acts by stimulating FOXO4 directly and not through 
Akt kinase which ultimately modulates FOXO1/3 
signaling [59]. While TNF- has been reported to 
augment the phosphorylation of Akt in cultured 
myotubes [59], TWEAK inhibits even the basal level of 
phosphorylation of Akt kinase in myotubes suggesting 
distinct modes of action of these catabolic cytokines 
[41]. Li et al. [60] have previously reported that TNF- 
also stimulates the release of reactive oxygen species 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Mechanisms of action of TWEAK in disuse atrophy. In normal healthy skeletal muscle, Fn14 expression is relatively 
low but it is drastically increased in various disuse conditions. Overexpression of Fn14 may promote its trimerization as is the 
case with many other members of TNF receptor super family. Binding of TWEAK to Fn14 results in activation of NF-B leading 
to increased expression of MuRF1 and atrophy.  
Denervation,
Immobilization,
Unloading, etc.
Receptor expression
and trimerization
TRAFs/cIAPs
NF-B
MuRF1 expression
Muscle proteolysis
Atrophy
Fn14
TWEAKThe TWEAK-Fn14 System  Current Molecular Medicine,  2012, Vol. 12, No. 1     7 
and the activation of p38 MAPK, which stimulates the 
expression of MAFbx. Additionally, activation/ 
expression of MuRF1 has been proposed as a 
mechanism by which TNF- down-regulates troponin T 
leading to loss of skeletal muscle function [61]. 
Although TWEAK induces the expression of MAFbx 
and MuRF1 [41] and the activation of p38MAPK in 
C2C12 myotubes [57], it remains to be investigated 
whether TWEAK also induces the expression of MAFbx 
or MuRF1 through augmenting oxidative stress and/or 
activation of p38MAPK. Similar to TNF- and TWEAK, 
a recent study by Li et al. [62] has demonstrated that 
both IL-1 and IL-1 cause significant atrophy when 
added to cultured myotubes. However, IL-1 acts 
through an oxidant- and Akt/Foxo-independent 
mechanism to activate p38 MAPK and stimulate NF-B 
leading to enhanced expression of MAFbx and MuRF1 
and myofibrillar proteolysis in C2C12 myotubes [62].  
One of the unique features of TWEAK that is not 
shared by TNF- or other muscle-wasting cytokines is 
its effect on NF-B signaling pathway. Depending on 
the type of stimuli, the activation of NF-B can occur 
via either a canonical or alternative pathway [63]. The 
canonical NF-B signaling pathway involves the 
upstream activation of inhibitors of B (IB) kinase- 
(IKK) and subsequent phosphorylation and 
degradation of IB proteins [63]. On the other hand, 
activation of the alternative NF-B pathway requires the 
upstream activation of NF-B-inducing kinase (NIK) 
and IKK and the proteolytic processing of p100 
subunit into p52 [63]. TNF- predominately activates 
the canonical NF-B signaling pathway [12] though 
there is also now evidence that continued presence of 
TNF- may also activate alternative NF-B pathway to 
some extent in myotubes [58]. By contrast, TWEAK is a 
potent activator of both canonical and alternative NF-
B signaling pathway in skeletal muscle [57]. 
Furthermore, while the effect of TNF- on NF-B 
activation is rapid and transient, TWEAK causes slow 
but sustained activation of NF-B in both myoblasts 
and myotubes [41, 64]. We believe that the stronger 
effects of TWEAK compared to TNF- on MyHC 
degradation in cultured myotubes [41], is attributed, at 
least in parts, to the TWEAK’s ability to cause 
sustained activation of NF-B, which stimulates the 
activity of UPS through augmenting the expression of 
MuRF1 and other components of proteasome [9, 65]. It 
is also noteworthy that the overexpression of a 
degradation-resistant mutant of IB (i.e. IBN) 
preserves the levels of MyHC in C2C12 myotubes in 
response to both TNF- and TWEAK suggesting that 
the activation of classical NF-B pathway 
predominately mediates the degradation of MyHC in 
response to both these cytokines [41, 66]. While the 
exact role of alternative NF-B signaling pathway in 
muscle wasting remains to be investigated, a recent 
study suggested that the alternative NF-B signaling 
pathway promotes mitochondrial biogenesis in 
differentiated myotubes [67]. However, in this study, 
the role of alternative pathway was studied in 
unchallenged myotubes [67]. The exact role of 
alternative pathway may depend on many factors 
including the type of stimuli and the length and level of 
activation of NF-B.  
IL-6 also causes loss of muscle mass; however, it 
appears that protein synthesis is suppressed more than 
proteolysis [68] which could be attributed to a reduction 
in Akt activity [69]. With regard to muscle proteolysis, 
circulating concentrations of IL-6 in the cachectic 
APC
min/+ mouse have been shown to increase MAFbx 
level and cause atrophy of type IIB fibers [70]. Other 
evidence suggests IL-6 may not increase MAFbx or 
MuRF1 [71]. IL-6 is increased in chronic kidney 
disease. This increase in IL-6 along with serum amyloid 
A impairs insulin/IGF-I signaling as indicated by Akt 
activity and results in muscle proteolysis [69].  
TWEAK AND FIBER-TYPE COMPOSITION 
Skeletal muscle of adult mouse contains four types 
of fibers: I, IIA, IIX, and IIB based on the MyHC isoform 
that is primarily expressed [72, 73]. MyHC type I fibers 
are “slow oxidative” that have high mitochondrial 
content, favor fatty acid oxidation, and have slower 
contraction/relaxation profile. MyHC type II fibers are 
called “fast glycolytic” fibers. Type IIA and type IIX 
fibers are fast oxidative/glycolytic fibers that have 
intermediate biophysical properties but tend to be 
oxidative too and rich in mitochondria [72, 73]. Adult 
skeletal muscle has enormous plasticity [74]. For 
example, endurance training induces fast-to-slow fiber 
type switch leading to improved endurance 
performance and resistance to fatigue. In contrast, 
resistance exercise induces hypertrophy, a slow-to-
fast-fiber transformation, and a switch to induce 
glycolysis as the favored energy source [74]. 
Interestingly, disuse and cancer cachexia cause not 
only atrophy but also induce slow-to-fast type fiber 
switch. Furthermore, different fiber-types display 
different sensitivity to atrophy; oxidative fibers are 
somewhat resistant to atrophy upon denervation [75] 
whereas glycolytic fibers undergo atrophy at a faster 
rate during starvation or sepsis than oxidative fibers 
[76, 77].  
Analyses of fiber-type composition in skeletal 
muscle of TWEAK-Tg and TWEAK-KO mice provided 
interesting results. Transgenic overexpression of 
TWEAK led to a significant reduction in type I fibers 
with a concomitant increase in type II fibers in both 
soleus and extensor digitorum longus (EDL) muscle 
[34]. Furthermore, hind limb muscle of the founder 
TWEAK-Tg mice which did not survive beyond 
neonatal age, appeared pale compared to more 
reddish muscle of wild-type littermates [41]. Moreover, 
compared to wild-type mice, an increased proportion of 
type I fibers was observed in skeletal muscle of 
TWEAK-KO [34] suggesting that TWEAK favors fast-
type fiber phenotype even in unchallenged skeletal 
muscle. 
The mechanisms by which TWEAK causes slow-to-
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investigated. Peroxisome proliferator-activated 
receptor-gamma (PPAR-) coactivator 1 (PGC-1) is 
a key player in regulating skeletal muscle fiber 
composition, mitochondrial content, and oxidative 
metabolism in both physiological and pathophysio-
logical conditions [78-80]. Transgenic mice expressing 
PGC-1 in skeletal muscle have increased proportion 
of fibers expressing MYHC I and IIA [81]. These effects 
of PGC-1 are mediated, at least in part, through 
augmenting the activity of MEF2 transcription factor, 
which induces type I fiber genes [82]. Interestingly, it 
was recently reported that TWEAK suppresses the 
expression of MEF2 in myofibers [56]. Accumulating 
evidence also indicates that PGC-1 preserves skeletal 
muscle mass in various catabolic states including 
denervation [83, 84]. There is a possibility that elevated 
levels of TWEAK increase the proportion of type II 
fibers through diminishing the expression of PGC-1. 
The potential relationship between TWEAK-Fn14 
system and PGC-1 is also suggested by the 
observations that the levels of PGC-1 in skeletal 
muscle go up after exercise [85-87]. In contrast, the 
levels of Fn14 are reduced below the basal level in 
exercised animals or in response to hypertrophy stimuli 
[34]. Since type II fibers undergo atrophy at faster rate 
compared to slow-type fibers, it is likely that TWEAK 
causes muscle loss by first inducing fiber-type 
transformation followed by the activation of various 
catabolic systems. Consistent with this hypothesis, 
recent studies have shown that TNF-, another 
muscle-wasting cytokine, down regulates the 
expression of PGC-1 in cultured myotubes [88, 89]. 
Experiments are in progress in our laboratory to 
determine whether crossing of PGC-1 Tg with 
TWEAK-Tg mice can prevent the slow-to-fast-type fiber 
transformation and muscle atrophy in TWEAK-Tg mice. 
Furthermore, it will be interesting to investigate whether 
exercise capacity and mitochondrial content are 
improved in TWEAK-KO and reduced in TWEAK-Tg 
mice compared to wild-type littermates and if so 
whether this occurs through modulation of expression 
of PGC-1.  
TWEAK/Fn14 SIGNALING IN MYOGENESIS 
Skeletal muscle formation or myogenesis is a 
complex and highly
 regulated process that involves the 
determination of multipotent
  mesodermal cells to 
generate myoblasts, exit of these myoblasts
 from the 
cell cycle, and their differentiation into muscle fibers 
[90, 91]. Myogenesis is regulated by the sequential 
expression of myogenic regulatory factors (MRFs), a 
group of basic helix-loop-helix transcription factors that 
include Myf5, MyoD, myogenin, and MRF4 [92]. During 
myogenesis, fusion of myoblasts into multinucleated 
myotubes is the terminal step of differentiation after 
which no further mitotic divisions occur within the 
myotubes or muscle fibers. The extra nuclei required 
for muscle growth are provided by satellite cells, which 
are located under the basal lamina of the muscle fiber 
[92].  
While TWEAK cytokine is widely expressed by a 
number of cell types, its receptor Fn14 is expressed 
only in selective cell types [23]. Fluorescence activated 
cell sorting and biochemical assays showed that Fn14 
is highly expressed in primary mouse myoblasts and 
C2C12 myoblastic cell line [33]. Cultured myoblasts 
respond to TWEAK by increased activation of various 
signaling pathways [33, 64]. Skeletal muscle of 
TWEAK-null or Fn14-null mice are normal [34, 37] 
suggesting that TWEAK and Fn14 are either not 
required or their deficiency is compensated by other 
factors present during muscle development. In 
contrast, increased levels of TWEAK affect both 
proliferation and differentiation of muscle progenitor 
cells. Addition of exogenous TWEAK protein augments 
proliferation but inhibits the differentiation of cultured 
myoblasts [64]. Analyses of TWEAK-treated cultures 
further showed that TWEAK reduces the levels of 
myogenin and MyoD in differentiating myoblasts [64]. 
While the levels of myogenin are diminished due to 
suppression of transcription, TWEAK stimulates the 
proteolytic degradation of MyoD in differentiating 
C2C12 cultures [64]. Furthermore, it was found that 
one of the mechanisms by which TWEAK inhibits 
myogenesis is through the activation of NF-B. TWEAK 
causes sustained activation of NF-B and the inhibition 
of NF-B through overexpression of a kinase dead 
mutant of IKK (an upstream activator of NF-B) or 
IBN (a degradation resistant mutant of NF-B 
inhibitory protein IB) rescued myogenic 
differentiation in TWEAK-treated C2C12 myoblasts 
[64]. Moreover, NF-B is responsible, at least in part, 
for the enhanced degradation of MyoD in TWEAK-
treated myoblasts [64]. These effects of TWEAK on 
myoblasts are consistent with published reports 
suggesting that other inflammatory cytokines also 
inhibit myogenic differentiation through the activation of 
NF-B and reducing the levels of MyoD [93, 94]. 
Activation of NF-B through canonical pathway 
generally inhibits the differentiation of myoblasts into 
myotubes [12, 67, 95] whereas the activation of NF-B 
through alternative pathway may have a positive role in 
mitochondrial biogenesis and maintenance of 
differentiated phenotype of myotubes [67]. 
Because TWEAK inhibits myogenic differentiation, it 
was hypothesized that the suppression of TWEAK 
receptor Fn14 in myoblasts would enhance their 
differentiation into myotubes. However, contrary to this 
presumption, knockdown of Fn14 by siRNA technique 
blocked the formation of myotubes in both C2C12 and 
mouse primary myoblast cultures [33]. Similar results 
were reported by Girgenrath et al. [37] where the 
authors showed that (a) Fn14 is highly expressed on 
muscle progenitor cells; (b) recombinant TWEAK 
protein inhibits myogenic differentiation by preventing 
cell cycle arrest in myoblasts; and (c) TWEAK 
suppressed the expression of both myogenin and 
MyoD in differentiating myoblasts [37]. Their study also 
showed that primary myoblasts from Fn14-null mice 
display significantly reduced proliferative capacity and 
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positive role of Fn14 in myogenesis [37]. These 
observations along with other published reports 
demonstrating that overexpression of Fn14 alone can 
induce various cellular responses including tumor cell 
migration and invasion [96-98] suggest that TWEAK-
independent Fn14 signaling also occurs which causes 
distinct biological responses compared to the settings 
where TWEAK is also present. Indeed, knockdown of 
Fn14 impaired the activation of RhoA GTPase and 
serum response factor in differentiating myoblasts 
providing a possible mechanism by which Fn14 might 
be regulating myogenic differentiation [33]. There is 
also a possibility that in the absence of TWEAK, Fn14 
predominantly activates promyogenic signaling 
pathways. Moreover, low levels of TWEAK may be 
required for proliferation of muscle progenitor cells. 
However, when TWEAK is present in sufficient amount 
to bind to Fn14, it leads to the activation of specific 
signaling pathways such as MAPKs and NF-B which 
may counter the promyogenic effects of Fn14 by 
inhibiting the withdrawal of myoblasts from cell cycle 
[33]. 
TWEAK/Fn14 SIGNALING IN SKELETAL 
MUSCLE REGENERATION 
Skeletal muscle regeneration is a multi-step process 
that involves the participation of a number of autocrine 
and paracrine factors [90, 91, 99]. The inflammatory 
response which starts within hours of injury and lasts 
up to seven days involves accumulation of neutrophils 
and
  macrophages which help removing tissue debris 
through phagocytosis in injured skeletal muscle [100]. 
These infiltrating phagocytes in injured skeletal muscle 
are also known to produce a number of cytokines and 
chemokines which can affect the proliferation and 
differentiation of satellite cells [100]. While it is now 
clear that the recruitment of phagocytes is critical for 
efficient regeneration of injured muscle, the roles of 
various proinflammatory and anti-inflammatory 
cytokines in skeletal muscle regeneration has not been 
yet clearly elucidated. Cell culture studies have 
suggested that inflammatory cytokines can modulate 
both the proliferation and differentiation of myogenic 
cells, however, the direct correlation between in vitro 
and in vivo studies is still lacking. There may also be 
some redundancy among cytokines regarding their role 
in skeletal muscle regeneration. For example, while 
TNF- strongly affects the survival, proliferation, and 
differentiation of cultured myoblasts [93, 94], skeletal 
muscle regeneration was normal in TNF-null mice 
[101].  
The  in vivo role of TWEAK in skeletal muscle 
regeneration has now been investigated employing 
both TWEAK-KO and muscle-specific TWEAK-
transgenic (Tg) mice [102]. The expression of both 
TWEAK and Fn14 is significantly elevated within 3-5 
days following cardiotoxin (CTX) injection, a known 
trigger for satellite cell-driven skeletal muscle 
regeneration [102]. When muscle regeneration was 
evaluated, no obvious difference in muscle structure 
was observed between wild-type, TWEAK-KO, and 
TWEAK-Tg mice, 5 days after CTX injection. However, 
at 10 and 21 days post CTX-injection, regenerating 
myofibers of TWEAK-KO mice appeared larger in 
diameter compared to wild-type mice [102]. By 
contrast, regenerating fibers were smaller in size in 
TWEAK-Tg mice compared to wild-type littermates 
[102]. Further analyses of muscle using biochemical 
and histological techniques showed that TWEAK 
mediates the inflammatory response leading to 
diminished regeneration and/or growth. The levels of 
activation of NF-B, expression of specific 
inflammation-related molecules, and interstitial fibrosis 
were significantly reduced in regenerating muscle of 
TWEAK-null mice and exacerbated in TWEAK-Tg mice 
compared to wild-type mice [102]. Although the exact 
mechanisms by which TWEAK regulates the size of 
regenerating myofibers is not clear, there are two 
possibilities which can account for the observed effects 
of TWEAK. First, it is possible that TWEAK by itself or 
in association with other inflammatory cytokines blocks 
the fusion of satellite cells resulting in reduced 
differentiation and growth of myofibers [64, 93]. 
Second, TWEAK may directly act on regenerating 
myofibers leading to the activation of various proteolytic 
systems and hence reduced fiber diameter [34, 41]. 
Together, these observations suggest that TWEAK 
inhibits the genesis and growth of skeletal muscle after 
injury. Reduced regeneration of myofibers after injury 
may be another determinant of TWEAK-induced 
skeletal muscle wasting (Fig. 3). 
It is interesting to note that the role of TWEAK and 
Fn14 in adult skeletal muscle regeneration is quite 
similar to their individual role in myogenic 
differentiation. Fn14-KO mice showed delayed muscle 
regeneration after injury [37]. Number of newly formed 
fibers with centronucleation and/or positive for 
embryonic form of myosin heavy chain was significantly 
reduced in Fn14-KO mice compared to wild-type mice 
in TA muscle at 5 and 7 days following cardiotoxin 
injection [37]. While muscle regeneration was almost 
complete by 14 days in wild-type mice, residual muscle 
damage along with regenerated fibers and 
inflammatory cells still persisted in Fn14-KO mice 
further suggesting fiber regeneration is diminished in 
Fn14-KO mice [37]. This study also suggested that the 
delayed muscle regeneration in Fn14-knockout mice 
could be attributed to diminished/delayed inflammatory 
response. Immune cells such as macrophages and 
neutrophils infiltrate muscle tissue within 1-3 days post 
CTX injection which helps removing tissue debris in 
injured muscle [100]. Concentration of both 
macrophages and neutrophils were significantly lower 
in Fn14-KO mice compared to wild-type mice 
measured 3 days post CTX injection [37]. Furthermore, 
it is likely that the delayed inflammatory response 
occurs due to suppression of expression of chemokine 
MCP-3 in Fn14-KO mice after CTX injection [37]. 
Certainly, more investigations are required to delineate 
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differentially regulate both myogenesis and adult 
skeletal muscle regeneration.  
CONCLUDING REMARKS 
The studies summarized above indicate that 
TWEAK-Fn14 system plays an important role in 
skeletal muscle remodeling. Most of these observations 
suggest that TWEAK-Fn14 signaling increases skeletal 
muscle loss and inhibition of this cytokine-receptor axis 
can be used as a therapy to preserving skeletal muscle 
mass in the conditions of atrophy and muscle injury. 
We believe that TWEAK-Fn14 system is among the 
most attractive drug targets for prevention of muscle 
wasting. Because TWEAK is an extracellular protein, 
TWEAK-dependent signaling can be blocked using a 
TWEAK neutralizing antibody or soluble Fn14-Fc decoy 
protein, which can prevent TWEAK binding to Fn14 cell 
surface receptors. Indeed, these two reagents have 
been found to improve pathology in animal models of 
some other diseases where TWEAK-Fn14 signaling is 
elevated. Alternatively, small-molecule antagonists that 
prevent Fn14 trimerization or interaction of TWEAK 
with Fn14 can also be used for blocking catabolic 
effects of TWEAK on skeletal muscle.  
Whereas the role of TWEAK-Fn14 signaling in 
skeletal muscle is increasingly clear, there are still 
many outstanding questions which need to be 
addressed. For example, it is important to identify other 
conditions in which TWEAK is a mediator of skeletal 
muscle atrophy. Since TWEAK inhibits the activation of 
PI3K/Akt pathway, it is likely that TWEAK might also be 
causing muscle atrophy in the settings of diabetes and 
starvation where drop in insulin levels and inhibition of 
PI3K/Akt pathway are the major mechanisms of muscle 
loss. The mechanisms by which TWEAK-Fn14 system 
causes muscle atrophy also require further 
investigation. While TWEAK has been found to induce 
the activation of NF-B and MuRF1, this cannot explain 
all the affects that TWEAK produces in skeletal muscle. 
For example, the mechanisms by which TWEAK 
induces fiber-type transformation in skeletal muscle 
remains to be investigated. Future studies focusing to 
examine the effects of TWEAK on expression of PGC-
1s and its associated transcription factors such as 
nuclear respiratory factor (NRF)-1 and NRF-2 may 
provide significant insight into the mechanisms of 
action of TWEAK leading to slow-to-fast-type fiber 
switch. It will also be interesting to examine whether 
TWEAK affects mitochondrial content by affecting the 
processes of mitochondrial biogenesis, fusion, and/or 
fission. TWEAK inhibits the expression of several micro 
RNAs (miRs) including muscle-specific miR1, miR133, 
and miR206, which could also be a potential 
mechanism by which TWEAK causes the loss of 
skeletal muscle mass in various catabolic conditions.  
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Fig. (3). TWEAK regulation of skeletal muscle biology. TWEAK-induced affects on muscle progenitor cells and adult skeletal 
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